Surasak Phuphanich, MD

Director, Neuro-Oncology Program

Professor, Neurology

127 S. San Vicente Blvd.
Advanced Health Sciences Pavilion, A6600
Los Angeles, CA 90048





Parking Instructions:

Parking is available in Lot 4 on Sherbourne Drive.

Surasak Phuphanich, MD

Director, Neuro-Oncology Program

Professor, Neurology

  • Neurology

Anaplastic Astrocytoma


Brain Cancers (Glioma)

Brain Tumors


Glioblastoma Multiforme

Headaches (Acute, Chronic, Tension, Rebound)




Meningeal Carcinomatosis




Spinal Cord Disorders

The clinical and research interests of Surasak Phuphanich, MD, are drug delivery with nano-particle through blood brain barrier (BBB) and drug discovery with focus on promising new Immunomodulation and targeted therapeutic agents. For example, PD-1/PDL-1 Antibody, M-Tor inhibitor, PI3 Kinase, Hedge-hog pathway, IDH1, EGFR-TKI, VEGFR, and immunotherapy with vaccine and stem cell for different specific cancer cell targets including correlation with proteinomic, genomic profile in order to avoid major side effects and maintain high quality of life in this group of patients with the ultimate goal of offering personalized Neuro-Oncology medicine for every patient with brain cancer.

  • Medical School: Mahidol University, 1975
  • Residency: Mahidol University, 1977
  • Internship: Saint Francis Hospital of Evanston, 1978
  • Residency: University of Illinois Hospital & Health Sciences System, 1981
  • Fellowship: University of California, San Francisco Medical Center, 1983

View CV as a PDF

  • America's Top Doctors for Cancer, Castle Connelly Medical Ltd., 2007-15
  • Editor: Current Cancer Therapy Reviews, 2006-15
  • Editor: Current Cancer Drug Targets, 2004-15
  • Editor: American Journal of Clinical Oncology, 2003-15
  • Best Doctors, Best Doctors, Inc., 2011-14
  • Top's American Physicians Award, Consumer Research Council, 2009-12
  • Patient’s Choice Award, MDx Medical, Inc., 2008-12
  • Georgia Cancer Coalition Distinguished Clinical Investigator Professorial Award, 2004

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62(1):125-135.
  • Chamberlain M, Grimm S, Phuphanich S, Recht L, Zhu J, Rosenfeld S, Fadul CE. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational consortium (BTIC). J Neurooncol. 2014;118(2):335-343.
  • Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17(3):430-439.
  • Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015;84(3):280-286.
  • Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212-3218.

Show moreShow less

English / Spanish / Thai

Make an Appointment




Available 24 Hours A Day


Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Surasak Phuphanich, MD